A Phase II Study of Amifostine for the Prevention of Acute Radiation-Induced Rectal Toxicity
The purpose of this study is to evaluate the effect of intrarectal Amifostine administration on acute radiation-induced rectal toxicity in pre-operative chemo-radiotherapy.
Rectal Cancer
DRUG: Amifostine
Acute radiation-induced toxicity: daily diarrhea frequency, about 3 months from chemo-raditherapy to operation
To evaluate the different use way of intrarectal Amifostine administration on acute radiation-induced rectal toxicity in pre-operative chemo-radiotherapy.